ESR1 and breast cancer: Similarly, HR+ (i.e., estrogen receptor (ER)‐ and/or progesterone receptor‐positive) BC patients have been found to develop resistance to hormonal therapies through ESR1 (OMIM 133430) mutations (Fanning et al., 2016; Osborne & Schiff, 2011).